Alfresa Holdings
Alfresa Holdings Corporation, commonly referred to as Alfresa, is a prominent player in the pharmaceutical distribution and healthcare industry, headquartered in Japan. Established in 2003, the company has rapidly expanded its operations across Asia, focusing on the distribution of pharmaceuticals, medical devices, and healthcare products. Alfresa is renowned for its commitment to quality and innovation, offering a diverse range of core services that include logistics, supply chain management, and pharmaceutical wholesaling. The company’s unique approach to integrating advanced technology in its operations has positioned it as a leader in the market. With a strong emphasis on customer satisfaction and a robust network of partnerships, Alfresa has achieved significant milestones, solidifying its reputation as a trusted provider in the healthcare sector. Its dedication to improving healthcare access and outcomes continues to drive its success in the competitive landscape.
DitchCarbon Score
How does Alfresa Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alfresa Holdings's score of 21 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Alfresa Holdings's reported carbon emissions
In 2023, Alfresa Holdings reported total carbon emissions of approximately 69,082,000 kg CO2e, comprising 32,399,000 kg CO2e from Scope 1 and 36,683,000 kg CO2e from Scope 2. This reflects a commitment to reducing emissions, with a short-term target of a 10% reduction by the end of FY2024 and a mid-term target of 30% reduction by the end of FY2030, using FY2020 emissions as a baseline. The company aims to achieve carbon neutrality by 2050, indicating a long-term strategy to address climate change across all scopes of emissions. Alfresa's proactive approach highlights its dedication to sustainability and environmental responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2013 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alfresa Holdings is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
